Inovio Pharmaceuticals (INO) Common Equity (2016 - 2025)
Historic Common Equity for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to -$7.7 million.
- Inovio Pharmaceuticals' Common Equity fell 11049.76% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.7 million, marking a year-over-year decrease of 11049.76%. This contributed to the annual value of $68.5 million for FY2024, which is 4162.39% down from last year.
- Latest data reveals that Inovio Pharmaceuticals reported Common Equity of -$7.7 million as of Q3 2025, which was down 11049.76% from $28.5 million recorded in Q2 2025.
- In the past 5 years, Inovio Pharmaceuticals' Common Equity ranged from a high of $581.6 million in Q1 2021 and a low of -$7.7 million during Q3 2025
- For the 5-year period, Inovio Pharmaceuticals' Common Equity averaged around $216.6 million, with its median value being $169.4 million (2023).
- Per our database at Business Quant, Inovio Pharmaceuticals' Common Equity soared by 20960.52% in 2021 and then tumbled by 11049.76% in 2025.
- Over the past 5 years, Inovio Pharmaceuticals' Common Equity (Quarter) stood at $399.7 million in 2021, then crashed by 44.36% to $222.4 million in 2022, then crashed by 47.23% to $117.3 million in 2023, then crashed by 41.62% to $68.5 million in 2024, then plummeted by 111.27% to -$7.7 million in 2025.
- Its last three reported values are -$7.7 million in Q3 2025, $28.5 million for Q2 2025, and $51.3 million during Q1 2025.